Salarius Pharmaceuticals Inc (SLRX)

06:53 AM

What analysts say about Salarius Pharmaceuticals Inc. stockExceptional earning trajectories - PrintWeekIndia

06:53 AM

06:19 AM

Is Salarius Pharmaceuticals Inc. a good long term investmentRapid market gains - PrintWeekIndia

06:19 AM

Jul 22, 2025

What drives Salarius Pharmaceuticals Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Salarius Pharmaceuticals Inc. Stock Analysis and ForecastRobust financial gains - jammulinksnews.com

Jul 22, 2025

Jul 21, 2025

Salarius Pharmaceuticals Modifies Security Holders’ Rights - TipRanks

Jul 21, 2025

Jul 21, 2025

Salarius Pharmaceuticals amends merger agreement to allow debt-for-equity exchange By Investing.com - Investing.com South Africa

Jul 21, 2025

Jul 21, 2025

Salarius Pharmaceuticals amends merger agreement to allow debt-for-equity exchange - Investing.com Australia

Jul 21, 2025

Jul 16, 2025

Salarius Pharmaceuticals (NASDAQ:SLRX) Trading Up 0.1% – What’s Next? - Defense World

Jul 16, 2025

Jul 15, 2025

How Salarius Pharmaceuticals Inc. stock performs during market volatilityFree Stock Market Return Analysis - Newser

Jul 15, 2025

Jul 15, 2025

Why Salarius Pharmaceuticals Inc. stock attracts strong analyst attentionFree Expert-Led Investment Training - Newser

Jul 15, 2025

Jul 15, 2025

What makes Salarius Pharmaceuticals Inc. stock price move sharplyShort Squeeze Radar - Newser

Jul 15, 2025

Jul 14, 2025

Salarius Pharmaceuticals granted additional extension to regain Nasdaq compliance - MSN

Jul 14, 2025

Jul 14, 2025

Salarius Pharmaceuticals Granted Extension to Regain Compliance With Nasdaq's Stockholders' Equity Requirement - MarketScreener

Jul 14, 2025

Jul 14, 2025

Salarius Pharmaceuticals Receives Extension for Nasdaq Compliance and Updates on Planned Merger with Decoy Therapeutics - Quiver Quantitative

Jul 14, 2025

Jul 14, 2025

SLRX gets Nasdaq extension; equity deadline moves to late-July 2025 | NDSN SEC FilingForm 8-K - Stock Titan

Jul 14, 2025

Jul 14, 2025

Salarius Pharmaceuticals Granted Additional Extension to - GlobeNewswire

Jul 14, 2025

Jul 14, 2025

Salarius Secures Critical Nasdaq Extension Amid $2.5M Equity Requirement Challenge - Stock Titan

Jul 14, 2025

Jul 10, 2025

Salarius Pharmaceuticals’ Seclidemstat Demonstrates - GlobeNewswire

Jul 10, 2025

Jul 09, 2025

Salarius Pharmaceuticals, Inc. Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - MarketScreener

Jul 09, 2025

Jul 09, 2025

Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - GlobeNewswire

Jul 09, 2025

Jul 09, 2025

Breakthrough Studies Support Salarius Cancer Drug Effectiveness While Clinical Trials Show Promise - Stock Titan

Jul 09, 2025

Jul 09, 2025

Salarius Pharmaceuticals reports progress in LSD1 inhibitor study, merger with Decoy Therapeutics. - AInvest

Jul 09, 2025

Jul 08, 2025

Salarius Pharmaceuticals shareholders approve reverse stock split and share issuance - Investing.com Nigeria

Jul 08, 2025

Jul 08, 2025

Salarius Pharmaceuticals Approves Reverse Stock Split - TipRanks

Jul 08, 2025